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HypertrophyHuman embryonic stem cell-derived cardiomyocytes (hESC-CM) are being developed for tissue repair and as a
model system for cardiac physiology and pathophysiology. However, the signaling requirements of their
growth have not yet been fully characterized.We showed that hESC-CM retain their capacity for increase in size
in long-term culture. Exposing hESC-CM to hypertrophic stimuli such as equiaxial cyclic stretch, angiotensin II,
and phenylephrine (PE) increased cell size and volume, percentage of hESC-CM with organized sarcomeres,
levels of ANF, and cytoskeletal assembly. PE effects on cell size were separable from those on cell cycle. Changes
in cell size by PE were completely inhibited by p38–MAPK, calcineurin/FKBP, and mTOR blockers. p38–MAPK
and calcineurin were also implicated in basal cell growth. Inhibitors of ERK, JNK, and CaMK II partially reduced
PE effects; PKG or GSK3β inhibitors had no effect. The role of p38–MAPK was conﬁrmed by an additional
pharmacological inhibitor and adenoviral infection of hESC-CMwith a dominant-inhibitory form of p38–MAPK.
Infection of hESC-CMwith constitutively active upstreamMAP2K3b resulted in an increased cell size, sarcomere
and cytoskeletal assembly, elongation of the cells, and induction of ANFmRNA levels. siRNA knockdownof p38–
MAPK inhibited PE-induced effects on cell size. These results reveal an important role for active protein kinase
signaling in hESC-CM growth and hypertrophy, with potential implications for hESC-CM as a novel in vitro test
system. This article is part of a special issue entitled, "Cardiovascular Stem Cells Revisited".asic human ﬁbroblast growth
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Human embryonic stem cells (hESC) are presently the stemcell type
with the greatest proven capacity for producing phenotypically
authentic cardiomyocytes (hESC-CM).While their use for cardiac repair
faces a number of logistical problems, they arewidely held to have great
promise as a potential human-based in vitro cardiomyocyte model
system for the cardiac researcher and the pharmaceutical industry. This
potential has been enhanced by the realization that both hESC and theirclose cousins, the induced pluripotent stem cells (iPSC), can be obtained
with disease-speciﬁc genotypes [1]. hESC-CM are stable in long-term
culture and show relative ease of genetic manipulation compared to
adult primary cardiomyocytes. Based on their gene expression patterns
and electrophysiological, morphological, and contractile properties, the
majority of hESC-CM initially resemble human immature cardiomyo-
cytes but have the capacity to develop in a number of respects [2–5].
Acute contractile and electrophysiological characteristics of hESC-CM
show promise in terms of reﬂecting the adult human phenotype [4,6,7],
andmodels of arrhythmia generation have already been described [8,9].
However, it is less obvious whether longer term responses of
hypertrophy, proliferation, and apoptosis, important for both cardiac
pathology studies and toxicology, would have similar ﬁdelity.
In this study,wehave focusedonhypertrophic responses inhESC-CM.
We have used canonical inducers of both pathological and physiological
hypertrophy(phenylephrine, angiotensin II, and stretch) andquantitated
theoutput in termsof awide rangeofhypertrophicmarkers. Importantly,
we have used high-content automatedmicroscopy to gather a number of
thesemeasurements, pointing theway towards high-throughput assays.
We have interrogated the mechanism underlying the hypertrophic
changes, initially using a broad screen of small molecule inhibitors for
some of the most widely known hypertrophic pathways. Selecting the
most active stimulus/inhibitor combination, we have veriﬁed the result
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constructs and downregulation using siRNA. Our results form a basis
for the use of hESC-CM as a hypertrophic model system for cardiac
research and drug discovery/toxicology.
2. Materials and methods
2.1. Differentiation and isolation of human embryonic stem cell-derived
cardiomyocytes
Cardiomyocytes were derived from human ESC line H7, which was
grown on Matrigel (BD Sciences)-coated plates with daily changes of
mouse embryonic ﬁbroblast (MEF)-conditionedmedium, supplemen-
ted with 8 ng/ml recombinant basic human ﬁbroblast growth factor
(bFGF, Invitrogen) and antibiotics (50 U/ml penicillin and 50 μg/ml
streptomycin). MEFs were isolated from 13 dpc MF-1 strain mouse
embryos and treated with mitomycin C (0.01 mg/ml, Sigma) at
passage 4. MEF-CM was prepared from mitotically inactive MEFs by
daily feeding/collecting hESC medium containing 80% KnockOut
DMEM (KO-DMEM), 20% KOSR, 1 mM L-glutamine, 10 mM non-
essential amino acids, antibiotics, 0.1 mM β-mercaptoethanol, and
4 ng/ml bFGF (all from Invitrogen) for up to aweek (150 ml/18.8×106
cells/T225 ﬂask). Human ESC were differentiated via embryoid bodies
(EBs) by mechanically breaking up the colonies after 3–10 min of
collagenase IV (Invitrogen) treatment to remove spontaneously
differentiated cells, followed by culturing in suspension culture in
low adherence plates for 4 days in differentiation medium (hESC
medium in which 20% KOSR was replaced by non-heat-inactivated
foetal calf serum) [6,10]. The EBswere plated out onto gelatine (0.5%)-
coated plastic dishes, and spontaneously beating areas, which
appeared from day 9 after EB formation, were microdissected from
EB outgrowths at around day 30 (range 25–40 days). In some
experiments, cells were isolated from beating clusters at other time
points after differentiation. Differentiated hESC in T175 ﬂasks or 10-
cm culture dishes were removed from the surface by treatment with
trypsin-EDTA (Sigma-Aldrich) for 5 min and collagenase IV for
10 min, counted and plated onto 96-well plates coated with 0.5%
gelatin. These were grouped either as 15 to 40 days (early), 41 to
60 days (intermediate) and 61–180 days (late) after differentiation.
For high-content measurements, cells were generated from dense
hESC monolayers, which were treated with human recombinant
Activin A (100 ng/ml, R&D Systems) (day 0–1), and bone morphoge-
netic protein 4 (BMP4, 10 ng/ml, R&D Systems) (days 1–5) in RMPI-
B27 medium (Sigma) [11]; spontaneously beating areas appeared
within 1–2 weeks after BMP4 withdrawal. Following dissociation of
clusters or monolayers into single cells, cells were seeded onto
gelatinized dishes and subjected to treatments after overnight
attachment in differentiation medium.
2.2. Use of phenylephrine, angiotensin II and cyclic mechanical stretch
To determine the effect of hypertrophic G-protein-coupled
receptor agonists, hESC-CMwere incubated in differentiationmedium
containing 10 μM α-adrenergic phenylephrine or 1 μM angiotensin II
(both Sigma) for 48 h. In separate sets of experiment, cultures of
isolated hESC-CMwere exposed to cyclic equiaxial mechanical stretch
in the presence of normal medium. Frequency of cyclic stretch was
0.5 Hzwith pulsation of 10–25% elongation of cells for 24 h. Cells were
stretched by applying a cyclic vacuum suction under Bioﬂex plates
with computer-controlled equipment (FX-2000; Flexcell Internation-
al). Control cultures remained on the plate without stretch.
2.3. Small molecule inhibitors of hypertrophy
To determine the effect of protein kinase inhibition on growth in
cell size and proliferation, selective small molecule p38 inhibitorSB202190 (1 μM, Sigma), PKG inhibitor KT5823 (1 μM), HDAC II
inhibitor trichostatin A (0.25 μM), ERK inhibitor PD98059 (10 μM),
JNK inhibitor SP600125 (1 μM), GSK3β inhibitor 1-azakenpaullone
(10 μM), CaMK II inhibitor KN93 (10 μM), calcineurin inhibitor
cyclosporine A (0.2 μM), mTOR inhibitor rapamycin (10 ng/ml), and
calcineurin/FKBP inhibitor FK506 (0.1 μM) were administered to
hESC-CM in the presence of absence of phenylephrine for 48 h. The
effect of phenylephrine was also tested in the presence of cell cycle
inhibitors: myosin II inhibitor blebbistatin (10 μM, for 48 h) and
synthetic anti-tubulin agent nocodazole (50 ng/ml, for 6 h). DMSO
was used as control and did not affect cell size.
2.4. Targeting of p38–MAPK by dominant negative p38–MAPK and
constitutively active MAP2K3b adenoviruses and p38 siRNA knockdown
For further characterization of p38–MAPK effects, we over-
expressed a dominant-negative form of p38α (p38αDN, a gift from
Dr. Yibin Wang) or constitutively active MAP2K3b (a gift from Dr.
Michael Marber) in hESC-CM. p38α DN was mutated in its dual
phosphorylation site (from T-G-Y to A-G-F), causing lack of kinase
activity. Cells were infected on day 1 in culture by adding titered
adenovirus to the culture medium at a multiplicity of infection (MOI)
of 4 or greater. The gene transfer efﬁciency of cultures was
determined through parallel infections with GFP adenovirus (Ad-
CMV-GFP). For siRNA knockdown, p38 siRNA (Ambion Silencer pre-
designed MAPK14, s3586, Applied Biosystems) transfection was
performed using Oligofectamine reagent (Invitrogen, 1 μl/well, ﬁnal
incubation volume 50 μl) per manufacturer's instructions. Scrambled
siRNA and mock transfection were used as negative controls.
2.5. Immunocytochemistry
Cells were ﬁxed with 4% paraformaldehyde, permeabilized with
0.2% Triton X-100, and labeled with anti-cardiac speciﬁc troponin I
(cTnI, Santa Cruz, 1:200 dilution), anti-Ki67 (proliferation marker,
Abcam, 1:100), anti-p38–MAPK (A-12, Santa Cruz, 1:100), anti-atrial
natriuretic factor (ANF, a marker of hypertrophy, Santa Cruz, 1:300),
Rhodamine–phalloidin (Invitrogen, 1:500), mTOR (Abcam, 1:100),
anti-sarcomeric myosin heavy chain (MF20, Hybridoma Bank, 1:200),
and anti-myosin heavy chain α/β (MHC α/β, clone 3-48, Abcam,
1:200) primary antibodies. Primary antibodies were detected with
FITC- (Abcam), Alexa 488- (Invitrogen), Alexa 546- (Invitrogen), and
Cy5- (Abcam) conjugated secondary antibodies (all 1:400). DNA was
visualized with DAPI (0.5 μg/ml; Sigma). Images were acquired on
Zeiss Axio Observer Z1 ﬂuorescence microscopy.
2.6. Plate imaging
Combinations of immunocytochemistry markers were used to
further characterize detailed phenotypic properties of hESC-CMculture.
The hESC-CM cultures were dissociated into individual cells before
treatment and plated at low density (up to 5000 cells per well of a 96-
well plate). Plates were scanned on ArrayScan™ VTi automated
microscopy and image analysis system (Cellomics Inc., Pittsburgh, PA,
USA) usingmodiﬁed Target Activation, Cell Cycle, Morphology Explorer
andCompartmentalAnalysis BioApplicationprotocols.Using the system
of automated highly sensitive ﬂuorescence imaging microscope with
10× objective and suitable ﬁlter sets, the stained cells were identiﬁed
with DAPI in ﬂuorescence channel 1, cTnI- or MHC α/β-Alexa 488 in
channel 2 and ANF-, and Ki67-Alexa546 in channel 3, respectively. The
arbitrary value calculated from the standard deviation of the intensity of
the pixels under the channel measuring DAPI reﬂected the content of
the intact and fragmented DNA. The maximal ratio of the MHC-positive
cells versus the whole differentiated hESC population was 45.4±3.5%
(from n=15 experiments, the average ratio was 20.4±3.3%, e.g.,
Fig. 1A). An approximate estimate showed that ~4×105 initial
Fig. 1. (A) Representative immunoﬂuorescence images showing differentiated hESC-CM-enriched culture and single hESC-CM stained positive for cardiac-speciﬁc atrial natriuretic
factor (ANF), troponin I, sarcomeric myosin MF20, and myosin heavy chain α/β (MHCα/β) as well as brightﬁeld (BF) image at 30 days after differentiation. Nuclei are stained with
DAPI (blue). Scale bar represents 50 μm. Bar graphs showing cell size (B), cell shape (length/width ratio) (C), and beating rate (D), and hESC-CMwith organized sarcomere structure
as a percentage of all MHCα/β-positive cells (E) in early (15 to 40 days after differentiation, n=6 preparations; light grey), intermediate (41 to 60 days, n=6; grey), and late
cultures (N60 days, n=6; dark grey). Results are shown as mean±SEM (one-way ANOVA **P≤0.01, ***Pb0.001 vs. early culture groups).
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~6×104hESC-CM. Fromeachwell, 1000–1500 total cellswereanalyzed,
giving aminimumof 100 cardiomyocytes (andonaverage, 2–300). Each
treatment was tested in triplicate wells, and the experiments were
repeated 3 times, except where indicated. Mean average intensities and
percentage of responders (those objects deemed 2 standard deviations
brighter than the average of the control cells) were recorded.
2.7. Cellular protein content
Cells were ﬁxed with 10% trichloroacetic acid (30 min), stained with
0.1 % (w/v) Naphthol Yellow S (Sigma, 30 min), and washed with 1%
acetic acid (30 min) [12]. DNA was visualized with DAPI. Cellular total
protein to DNA content ratio was analyzed on Cellomics platform by
Target Activation Bioapplication. Protein to DNA ratio was further
veriﬁed by measuring the ratio of absorptions at 260 vs. 280 nm
wavelengths with spectrophotometer (NanoDrop 8000, Thermo Fisher).
2.8. Isolation of RNA
Undifferentiated and differentiated hESC cultures were lysed in
RLT buffer for total RNA extraction as per manufacturer's protocol(Qiagen, CA). Total RNA was obtained from human left ventricular
tissue explanted during transplant surgery. The RNA was puriﬁed
using RNeasy columns (Qiagen, CA), quantiﬁed, and checked for
quality on a denaturing 1% agarose gel. To generate double-stranded
cDNA, 1 μg of total RNA was used for RT2 First Strand Kit
(SABiosciences, MD) or High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, CA), according to published protocols.
2.9. Quantitative RT-PCR and PCR array
For quantifying mRNA levels of ANF, p38–MAPK, αMHC, βMHC,
SERCA2a, and the ryanodine receptor2 in differentiated hESC cultures,
real-time PCR analyses were performed with TaqMan Gene Expres-
sion Assays (Hs00383230_g1, Hs01047706_m1, Hs00411887_m1,
Hs01110632_m1, Hs01566028_g1, and Hs00892842_m1, respective-
ly, Applied Biosystems, CA). GAPDH Endogenous Control (FAM/MGB
probe) was used as a housekeeping control. For PCR array, the cDNA
was hybridized in a 96-well format against the Gene Array PAHS-018
with RT2 qPCR Master Mix, which contained SYBR green dye (RT2
Proﬁler™ PCR Array System, SABiosciences) as per the manufacturer's
instructions. The array contains primers for ELK1, FOS (c-Fos), JUN,
and NFκB. The PCR was performed with ABI 5700 (Applied
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instruments, and the relative expression was determined by ΔΔCt
method in which fold increase=2−ΔΔCt.2.10. Volume measurements of hESC-CM
Hopping mode scanning ion conductance microscopy was used to
estimate the volume of live and ﬁxed isolated hESC-CM [13]. A glass
micropipette probe ﬁlled with electrolyte is connected to a high-
impedance, head-stage current ampliﬁer and mounted on a comput-
er-controlled three-axis translation stage. Control electronics drive
the translation stage to scan the cells under the micropipette probe.
The position of probe tip, in relation to the sample surface, inﬂuences
the ion current through the pipette. The ion current provides a signal
for the feedback loop, which controls the vertical axis of the
positioning system. Whole-cell volume was estimated as described
earlier [14].2.11. Statistics
Results are expressed as mean SEM. The data were analyzed by
unpaired Student's t test or one-way analysis of variance and the
Fisher's protected least signiﬁcant difference test for multiple
comparisons. Differences at the level of Pb0.05 were considered
statistically signiﬁcant.Fig. 2. Phenylephrine-induced hypertrophy of hESC-CM. The hESC-CM underwent phenyleph
ion conductance microscopy images of control (left image) and PE-treated (right image) hE
Rhodamine–phalloidin (red), MHC (green), and DAPI. Scale bar represents 50 μm. (C) Bar
organized sarcomeres, ANF mRNA and intensity levels, F-actin distribution, and total protei
control group. The percent of MHC-positive cells with organized sarcomeres was 19.5±4.3 in
MHC-positive cells analyzed per well, mean±SEM of triplicate wells, repeated in n=3 pre3. Results
3.1. hESC-derived cardiomyocytes increase in size during prolonged culture
Embryoid bodies derived from H7 line showed spontaneous
contractile activity from 9 to 15 days after induction of differentiation.
hESC-CM isolated from EBs stained positive for atrial natriuretic factor
(ANF), and sarcomeric proteins typical of myocytes, such as
sarcomeric myosin heavy chains (clone 3–48 and MF20) as well as
cardiac troponin I (Fig. 1A). In long-term cultures (for a period up to
6 months), hESC-CM increased in cell size and beating rate and
showed amodest elongation after a steady-state period of 40 days (all
Pb0.01) (Fig. 1BCD). The percentage of hESC-CM with organized
sarcomere structures was similar in early (15 to 40 days after
differentiation), intermediate (41 to 60 days), and late cultures
(N60 days) (29±3%, 27±1% and 28±2%, each n=6 cultures,
respectively, PN0.05, ANOVA) (Fig. 1E).3.2. Expressions of hypertrophy-related genes are upregulated in
differentiated hESC cultures
To investigate the temporal expression of hypertrophy-related
structure proteins, transcription factors, calcium modulators, and
atrial natriuretic factor (ANF), total RNA was collected from
undifferentiated hESC and early, intermediate, and late differentiated
cultures. As assessed by quantitative RT-PCR, mRNA levels of growth-rine treatment (10 μM, 48 h) 30 days after differentiation. (A) Representative scanning
SC-CM. (B) Representative immunoﬂuorescence image showing hESC-CM stained with
graphs showing fold change in cell area, estimated whole cell volume, hESC-CM with
n/DNA content ratio in hESC-CM treated with PE: results are shown as fold changes vs.
control vs. 65.2±5.6 in phenylephrine-treated group, from n=6 preparations. (n N100
parations. *P≤0.05, **Pb0.01, ***Pb0.001 vs. control group).
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Fig. 3. Cyclic stretch and angiotensin II-induced increase in cell size, sarcomere
alignment, and hypertrophic gene activation. The hESC-CM underwent cyclic stretch
(0.5 Hz with pulsation of 10–25% elongation of cells, 24 h, (A) and angiotensin II
treatment (1 μM, 48 h; (B) 30 days after differentiation. Bar graphs show fold change in
cell size, hESC-CMwith organized sarcomeres and ANF,αMHC, and βMHCmRNA levels
measured by quantitative PCR. mRNA results are expressed as ratio of mRNA to GAPDH
(n N100 MHC-positive cells analyzed per well, mean±SEM of triplicate wells, repeated
in n=3 preparations, *Pb0.05, ***Pb0.001 vs. control).
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Pb0.001, elk-1: 9.5-fold, Pb0.0001, and NFκB: 2.3- fold, Pb0.001, at
1 month after differentiation) were signiﬁcantly upregulated in
differentiated hESC as compared with undifferentiated hESC. Expres-
sion levels of α and βMHC showed a marked increase after 68 days
bringing αMHC expression to the range of the adult failing sample
used, although βMHC was still somewhat lower. The α/β ratio was
higher in hESC-CM than in the adult failing sample, or than has been
reported for normal human ventricle where αMHC comprises only
30% of total [15] (Supplementary Fig. 1ABC). The mRNA levels of
calcium handling cardiac ryanodine receptor (RyR2) and sarcoplasmic
reticulum Ca2± ATPase (SERCA2a) were upregulated in later stage
cultures compared to early hESC-CM (Supplementary Fig. 1DE). The
mRNA levels of ANF were robustly induced in the early, intermediate,
and late stage beating clusters as compared with undifferentiated
hESC (Supplementary Fig. 1F).
3.3. Phenylephrine, cyclic stretch, and angiotensin II induce cellular
hypertrophy of hESC-CM
Next we investigated the effects of putative hypertrophic stimuli
on hESC-CM. Administration of an α-adrenoceptor/Gq agonist
phenylephrine (PE, for 48 h) resulted in a signiﬁcant increase in cell
area (1.8-fold, Pb0.0001), number of hESC-CM with organized
sarcomere structure (3.8-fold, Pb0.0001), and perinuclear immuno-
reactive ANF intensities (2.1-fold, Pb0.001) and ANF mRNA (Fig. 2C).
Hopping mode ion conductance scanning microscopy showed that PE
markedly increased average volume of hESC-CM (2-fold, Pb0.001,
Fig. 2AC). Administration of PE resulted in a cytoskeletal rearrange-
ment such as altered cellular distribution of F-actin, indicative of
myoﬁbril thin ﬁlaments (as well as stress ﬁber formation) (Fig. 2BC).
Total cellular protein to DNA content was signiﬁcantly higher in PE-
treated cells (7-fold higher for the whole culture by Nanodrop, and
2.1-fold higher, Pb0.0001, n=55, for MHC-positive cells, Fig. 2C).
Similarly to PE, stretching hESC-CM for 24 h resulted in an increase in
cell size (1.6-fold, Pb0.001, Fig. 3A). Cyclic stretch resulted in a
signiﬁcant increase in the percentage of hESC-CM with organized
sarcomere structure after 24 h (Pb0.001, Fig. 3A). αMHC, βMHC, and
ANFmRNA levels were increased in response to cyclic stretch (Pb0.05
and 0.001 vs. unstretched control, respectively, triplicate determina-
tions). The incubation with angiotensin II (100 μM, 48 h) resulted in a
more modest but signiﬁcant increase in cell size (1.2-fold, Pb0.05) as
well as a greater percentage of hESC-CM with organized sarcomeres
and raised αMHC, βMHC, and ANF mRNA levels (Fig. 3B). The α/β-
MHC ratio did not change signiﬁcantly in response to stretch,
phenylephrine, or angiotensin II after 48-h treatment.
3.4. Small molecule hypertrophy inhibitors decreases cell size in
hESC-CM
To identify the canonical hypertrophy pathways mediating effects
of PE, we treated hESC-CM with small molecule protein kinase
inhibitors for 48 h. Comparison with PE alone showed signiﬁcant
differences in cell size after inhibition of p38–MAPK (SB202190),
HDAC II (trichostatin A), ERK (PD98059), JNK (SP600125), CaMK II
(KN93), mTOR (rapamycin), calcineurin (cyclosporine A), and calci-
neurin/FKBP (FK506) (Fig. 4A). A further analysis additionally
comparing control hESC-CM size revealed that there remained
signiﬁcant differences after ERK, JNK, and CaMK II inhibition,
indicating that PE-induced growth was not completely abolished.
Inhibition of PKG (KT5823) and GSK3β (1-azakenpaullone) had no
signiﬁcant effect on cell size in PE groups (P=0.06 and 0.7,
respectively), and these remained signiﬁcantly increased compared
to DMSO control. Inhibition of p38–MAPK, calcineurin, andmTOR also
reduced basal cell size in the absence of PE (Pb0.05). The majority of
inhibitors reduced PE-induced increase in ANF mRNA levels, althoughlevelswere too variable to distinguish the strength of individual effects
(Fig. 4B). In line with earlier studies [16,17], ANF expression remained
stimulated despite rapamycin treatment.
3.5. Effect of p38–MAPK inhibition on hESC-CM growth
The p38 MAPK inhibitor SB202190 showed the strongest inhibi-
tion of spontaneous cell growth (whichmay be driven by serum or the
continuous beating) and reduced the effects of PE. Similarly, the cyclic
stretch-induced increase in cell size and sarcomere alignment were
abolished by SB202190 (Pb0.001) (Supplementary Fig. 2AB). We
therefore used more stringent methods to conﬁrm the role of p38–
MAPK in basal cell growth and PE-induced hypertrophy of hESC-CM.
We found that the mRNA levels of p38–MAPK were strongly
upregulated in differentiated cultures (up to 26,000-fold, Pb0.0001
vs hESC). In addition to earlier microarray surveys of differentiating
hESC [3,18], our quantitative RT-PCR array showed that differentiation
was associated with a transient upregulation of proximal regulatory
kinases of p38–MAPK such as MAP2K3 (1.4-fold, Pb0.01). Silencing of
p38–MAPK by siRNA abolished PE-induced increase in cell size
(Pb0.001) (Fig. 5A). Inhibition of p38–MAPK had tonic effects to
decrease hESC-CM size even in the absence of added hypertrophic
stimuli (Supplementary Fig. 3A). Administration of either SB202190
or SB203580, another inhibitor with different speciﬁcity and off-
target effects, caused a modest elongation of the cells (+7% and
+11% vs. control hESC-CM, respectively, Pb0.05) (Supplementary
0 1 2 3 4
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Fig. 4. Small molecule inhibitors on phenylephrine-induced hESC-CM hypertrophy. Bar graphs showing cell size relative to control (A) and ANF mRNA (B) of hESC-CM treated with
PE in the presence of selective p38–MAPK inhibitor SB202190 (1 μM), PKG inhibitor KT5823 (1 μM), HDAC II inhibitor trichostatin A (0.25 μM), ERK inhibitor PD98059 (10 μM), JNK
inhibitor SP600125 (1 μM), GSK3β inhibitor 1-azakenpaullone (10 μM), CAMK II inhibitor KN93 (10 μM), calcineurin inhibitor cyclosporine A (0.2 μM), mTOR inhibitor rapamycin
(10 ng/ml), and calcineurin/FKBP inhibitor FK506 (0.1 μM) for 48 h. (For cell size, n N100 MHC-positive cells analyzed per well, mean±SEM of triplicate wells, repeated in n=3
preparations. For mRNA levels, triplicate wells, repeated in n=2 preparations. One-way ANOVA **Pb0.01, ***Pb0.001 vs. PE-group; #Pb0.001 vs. DMSO-control group.)
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(Supplementary Fig. 3C). Similarly, infection of hESC-CM with a
dominant-negative form of p38α lacking kinase activity decreased
cell size after 48 h (at MOI: 5, by 29±5% vs. GFP adenovirus-infected
cells, Pb0.001) (Supplementary Fig. 3A) although without changing
shape (P=0.80) (Supplementary Fig. 3B). The percentage of hESC-CM
with organized sarcomeric structure in unstimulated cultures was
unchanged by SB202190 or dominant-negative p38–MAPK (P=0.96).
3.6. Constitutively activeMAP2K3 induces hypertrophic growth of hESC-CM
To investigate directly the effects of activating p38–MAPK, we
infected hESC-CM with recombinant adenovirus expressing a consti-tutively active form of the upstream activator MAP2K3b (Fig. 5B).
Infection resulted in an increased cell size, signiﬁcantly higher
percentage of hESC-CM with organized sarcomeres, cytoskeletal
rearrangement (all Pb0.0001 vs. GFP adenovirus-infected cells,
48 h), elongation of the cells (+12% vs. GFP control, P=0.02), and
induced ANF mRNA levels (1.7-fold, Pb0.05). Furthermore, constitu-
tive activation of MAP2K3b resulted in formation of binuclear hESC-
CM (relative increase in binuclear hESC-CM percentage at 2 MOI: 4-
fold, 5 MOI: 2.8-fold, and 10 MOI: 2.1-fold vs. GFP control, all
Pb0.001). This together suggests that hESC-CM infected with
constitutively active MAP2K3b are undergoing cellular hypertrophy.
Activation ofMAP2K3b did not change absolute cell numbers (P=0.9)
or the percentage of cellswhichwereKi67+/MHC+ (P=0.3). Infection
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Fig. 5. (A) Bar graphs showing cell size of hESC-CM (~30 days) treated with phenylephrine (10 μM, 48 h) in the presence of p38–MAPK or scrambled control (NT) siRNA.Mean±SEM
of triplicate wells, repeated in n=3 preparations. ***Pb0.001 vs. mock control group; #Pb0.001 vs. phenylephrine-treated group. (B) Infection of hESC-CMwith constitutively active
MAP2K3b recombinant adenovirus. Bar graphs showing fold changes in cell area, hESC-CMwith organized sarcomeres, F-actin distribution, ANFmRNA levels, percentage of binuclear,
and Ki67-positive hESC-CM infectedwith constitutively active MAP2K3b-adenovirus vs. control GFP adenovirus group. (n N100MHC-positive cells analyzed per well, mean±SEM of
triplicate wells, repeated in n=3 preparations. One-way ANOVA.*Pb0.05, **Pb0.01, ***Pb0.001 vs. control group.)
373G. Földes et al. / Journal of Molecular and Cellular Cardiology 50 (2011) 367–376with GFP adenovirus did not change basal cell size, or the response to
phenylephrine (data not shown).
3.7. Phenylephrine regulates cell size independently of cell cycle
To investigate whether the effect of hypertrophic agonist PE on cell
size can be dissected from cell cycle checkpoints, hESC-CM were
treated with cell cycle inhibitors. At 30 days after differentiation, the
ratio of Ki67-positive hESC-CM was similar in PE-treated and control
cells (P=0.34), suggesting that PE did not modulate proliferative
capacity. Administration of blebbistatin, a myosin class II inhibitor,
blocked cytokinesis of proliferating hESC-CM, resulting in formation
of binuclear cells (Fig. 6AC). Blebbistatin augmented the PE-induced
increase in cell size (Pb0.01, Fig. 6B). The percentage of Ki67-positive
hESC-CM was similar in the control and blebbistatin-treated cultures,
whereas blebbistatin increased Ki67 labeling in PE-treated cells
(Fig. 6D). As assessed by Arrayscan analysis, the distribution of cells
in G2/M and G1/G0 cell cycle phases in the control and blebbistatin-
treated cultures was comparable (Fig. 6E). Cells treated with another
cell cycle inhibitor, nocodazole, arrested with a G2/M-phase DNA
content (Fig. 6E). Nocodazole had no effect on PE-induced changes in
cell size (data not shown), further suggesting that PE can increase cell
size independently from cell cycle.
The number of hESC-CM and the distribution of cells in cell cycle
phases were similar in control and SB202190-treated groups
(P=0.66) (Supplementary Fig. 3D). Similarly, dominant-negative
p38–MAPK vs. GFP control groups had comparable Ki67 ratios
(P=0.84).
4. Discussion
We have demonstrated that hESC-CM undergo growth either
spontaneously with prolonged time in culture or more markedly after
the canonical physiological or pathological stimuli, phenylephrine
(PE), angiotensin II, or stretch. Use of increase in cellular area as a
marker was supported by similar increases in volume and protein/
DNA ratio. Modest changes in length/width ratio were occasionally
observed, but it is not surprising that the adult elongated cardiomyo-
cyte morphology did not develop in the absence of an anisotropic
stimulus. Relating this to current models of hypertrophy, furthereffects observed were an increase in the number of hESC-CM with
organized sarcomeric structures and a rearrangement in cytoskeletal
organization. Despite signiﬁcant basal levels, hypertrophic stimuli
produced a marked increase in ANF in early-stage hESC-CM. A variety
of interventions demonstrated the independence of the effects on
growth from those on cell cycle progression. The range of morpho-
logical and expression markers that are altered in response to the Gq
agonists and stretch was well matched between hESC-CM and rat
neonatal cardiomyocyte models [19].
An initial broad sweep of the major pathways implicated in
hypertrophy was made using small molecule inhibitors at optimal
concentrations taken from literature on current rat and mouse
models. This is an equivalent strategy to current medium- or high-
throughput industry screens to generate initial targets. Complete
inhibition of PE-induced cell size change was seen with inhibitors of
p38–MAPK and calcineurin/FKBP and mTOR. p38–MAPK and calci-
neurin were also implicated in spontaneous development, since
inhibitors decreased cell size in the absence of PE. Inhibitors of HDAC
II, ERK, JNK, and CaMK II reduced PE effects but did not completely
abolish them. Differences could be concentration-related: typically
the more complex screens will use a range of inhibitor concentrations
to determine IC50 values and so assess speciﬁcity and maximum
response. PKG or GSK3β inhibitors had no effect on basal or PE-
induced increases in hESC-CM size: it is interesting that neither
demonstrated the potentiation of PE effects that might be expected
given the role of these pathways in opposing hypertrophy [20,21].
We went on to verify the observations from the broad screen,
which had identiﬁed the p38 MAPK inhibitor as most potent in
reducing basal and PE-induced cell growth. The role of p38–MAPK in
the spontaneous increase in hESC-CM size in culturewas conﬁrmed by
an additional pharmacological inhibitor and adenoviral transfection of
a dominant-inhibitory form of p38–MAPK. We further showed that
infection with recombinant adenovirus containing constitutively
active form of upstream MAP2K3b resulted in an increased cell size,
sarcomere and cytoskeletal assembly, elongation of the cells, and
induction of ANFmRNA levels. Of note, the ratio of binuclear hESC-CM
was signiﬁcantly higher in the constitutive active MAP2K3b group.
siRNA knockdown of p38–MAPK inhibited PE-induced effects on cell
size. These characteristics strongly suggest that active p38–MAPK
signaling causes hypertrophic growth of hESC-CM in vitro. The
Fig. 6. Phenylephrine modulates cell size independently of cell cycle. (A) Representative immunoﬂuorescence image showing hESC-CM stained positive for the myosin heavy chain
α/β (MHCα/β, green), DAPI (blue), Ki67 (nuclear, red), and atrial natriuretic factor (ANF, perinuclear, orange) in the presence of cell cycle inhibitor blebbistatin (10 μM) at 30 days
after differentiation. Scale bar represents 50 μm. Bar graphs showing cell size of hESC-CM (B), percentage of binucleated hESC-CM (C), and percentage of Ki67-positive hESC-CM (D)
treated with phenylephrine (PE) in the presence of blebbistatin (Bleb, solid bar) or vehicle (light grey bar). Results are shown as mean±SEM (n N100 MHC-positive cells per well, in
triplicate, n=2 preparations). The Cellomics Cell Cycle BioApplication classiﬁed hESC-CM treated with blebbistatin, nocodazole, or control medium into their cell cycle phase based
on the total nuclear intensity of DNA binding DAPI (E). Cell cycle distribution presented as histogram where the Y-axis represents the number of instances and the X-axis represents
the total nuclear intensity. The positions of the 2 N and 4 N DNA contents as well G0/G1, G2/M, and S phases are indicated (n=600 from 3 experiments). *Pb0.05 vs. control,
***Pb0.001 vs. control, #Pb0.001 vs. respective vehicle-treated group.
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development in hESC, since it has been implicated in the direction of
differentiation to favor cardiomyogenesis [22–24] and previous
studies indicated the presence of p38–MAPK in hESC as well as in
differentiating embryoid bodies [24,25]. However, the involvement of
p38–MAPK in hypertrophic remodeling has been controversial.
Reduction of hypertrophy by small molecule inhibitors of p38–MAPK
has been seen in various rat, mouse, and hamster models [26–28], but
transgenic manipulation has not generally supported such a role
(though the embryonic lethality from p38α knockout has made these
experiments technically difﬁcult) [29].
When results differ in this way between animal models and hESC-
CM/iPSC-CM, with their human genetic background, it will be
interesting to see how the balance of evidence is weighed. One
reason for differences may be the immature phenotype of the hESC-
CM especially at early time points. In the present study, we showed
that expression of myosin heavy chain isoforms, SERCA2, andryanodine receptor 2 increased strongly 2 months after differentiation
of hESCs. These changes would tend to be associated with maturation,
and this is approximately the duration over which other indicators of
development are seen, such as upregulation of repolarization-related
K+ channels, resistance to arrhythmias, and development of intra-
cellular Ca2+ stores [4]. However, the immaturity of hESC-CM must
remain a signiﬁcant caveat.
Obviously, we have not been exhaustive in exploring all the known
hypertrophic pathways and have not even considered those newly
identiﬁed from genomic, transcriptomic, or proteomic arrays. How-
ever, it is clear from both this study and the wealth of literature
[30,31] that there are multiple interacting pathways controlling
aspects of hypertrophy. Numerous reviews show the interconnections
and redundancy of the control systems and the emergent properties
that arise from these complex relations [32,33]. The challenge is now
to apply network systems biology to identify key control points that
coordinate multiple signal inputs and then produce graded outputs of
375G. Földes et al. / Journal of Molecular and Cellular Cardiology 50 (2011) 367–376cardiac growth [34]. The techniques and data described here show
that one advantage of hESC-CM is their suitability for high-throughput
methodologies, which will match functional cellular outputs to array-
generated information. An exciting aspect of hESC-CM or iPSC-CM is
the ability to compare cells directly with individual patient responses
for particular mutations or haplotypes. For example, iPSC-CM have
recently been generated from patients with LEOPARD syndrome,
which include a hypertrophic phenotype [35]. In vitro these iPSC-
derived cardiomyocytes had a greater cell size, more sarcomeric
organization, and high nuclear NFATC4 than controls, although ANF,
protein/DNA ratio and volumewere not assessed. Efforts such as these,
as well as the comparisons being undertaken by pharmaceutical
industries for clinical predictivity of hESC-CM, relative to current in
vivo and in vitro screens, will allow an understanding of the ﬁdelity of
response of hESC-CM to adult heart. Ultimately, only clinical trials can
assesswhether a givenmodel has been of use in predicting compounds
that will be effective against human disease.
5. Conclusions
HESC-CM have continued capacity to increase in size after
differentiation, and growth is stimulated by classical physiological
and pathological hypertrophic agents. Effects of small molecule
inhibitors indicated the involvement a number of knownhypertrophic
pathways in this process, including p38–MAPK, calcineurin, FKBP,
mTOR,HDAC II, ERK, JNK, andCaMK II. These results represent the basis
for development of hESC-CM as a tool for the cardiac researcher or
pharmaceutical industry, while the methodologies used may lead to
high-throughput small molecule or RNAi screens to investigate
hypertrophic and anti-hypertrophic responses. Establishment of the
phenotypic ﬁdelity of hESC-CM and their subsequent incorporation
into humanized, high-throughput, genotype-speciﬁc models could
produce a step change in productivity for the cardiac researcher.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.yjmcc.2010.10.029.
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Cell proliferation:The term is used in the contexts of cell development and cell division. It
refers to growth of cell populations, where one cell grows and divides to produce two.
Differentiation: The process whereby an unspecialized embryonic stem cell acquires the
features of a specialized cell, such as a heart, liver, or muscle cell.Embryoid bodies (EBs): Clumps of cellular structures that arise when embryonic stem
cells are cultured. Embryoid bodies contain tissue from all three germ layers:
endoderm, mesoderm, and ectoderm. Embryoid bodies are not part of normal
development and occur only in vitro.
Embryonic stem cells: Primitive undifferentiated cells derived from the early embryo
that have the potential to become a wide variety of specialized cell types.
